Advances in biologic and small molecule therapies for hidradenitis suppurativa.
Stella X ChenCharlotte GreifRuby S GibsonMartina L PorterAlexa B KimballPublished in: Expert opinion on pharmacotherapy (2022)
Trial data and our own experience have shown that about half of HS patients experience improvement with adalimumab. However, there is a significant need for pharmacotherapies with higher efficacy goals as in those used for psoriasis. Many biologics and small molecule inhibitors are being tested in clinical trials. The landscape of upcoming therapies for hidradenitis suppurativa appears promising.
Keyphrases
- hidradenitis suppurativa
- small molecule
- clinical trial
- end stage renal disease
- rheumatoid arthritis
- protein protein
- ejection fraction
- newly diagnosed
- chronic kidney disease
- phase ii
- study protocol
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- phase iii
- public health
- systemic lupus erythematosus
- big data
- juvenile idiopathic arthritis